# Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Phase 2 study closed enrollment, 44 enrolled (Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Sponsor type | Academic and hospital |
| Study | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance |
| NCT ID | NCT03114865 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Acute Lymphoblastic Leukemia; B-cell Non Hodgkin Lymphoma; Pre B-Cell Acute Lymphoblastic Leukaemia |
| Intervention types | drug |
| Target enrollment | 44 |
| Site countries | United States |
| Posted | 2017-04-14 |
| Planned start | 2017-09-05 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03114865). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.